Valuation: Guided Therapeutics Inc

Market Cap 2.65Cr 2.33Cr 2.16Cr 1.98Cr 3.74Cr 255.67Cr 3.79Cr 26Cr 10Cr 125.3Cr 9.97Cr 9.75Cr 432.64Cr P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 2.94Cr 2.58Cr 2.39Cr 2.2Cr 4.15Cr 283.37Cr 4.2Cr 29Cr 11Cr 138.88Cr 11Cr 11Cr 479.51Cr EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 06/03/2023
Chief Tech/Sci/R&D Officer 70 02/12/2010
Director TitleAgeSince
Director/Board Member 70 01/12/2016
Director/Board Member 76 10/04/2006
Chairman 67 01/10/2013
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-2.12%+29.09%-7.02% 20TCr
-11.39%-10.21%-4.97%-30.15% 14TCr
+1.23%-5.88%-30.79%+6.10% 13TCr
-1.43%+1.21%-58.43%-18.84% 6.51TCr
-1.45%-7.17%+9.23%-9.66% 4.89TCr
-2.38%+0.64%-24.65%-32.78% 4.49TCr
+2.15%-1.70%+18.61%+4.13% 3.68TCr
+2.21%-3.00%+29.62%+26.45% 3.51TCr
-1.30%+1.48%-24.98%-10.95% 2.86TCr
Average -1.38%-3.21%-6.36%-8.08% 8.03TCr
Weighted average by Cap. -2.36%-2.97%-3.21%-10.11%

Financials

2024 2025
Net sales 7T 6.14T 5.68T 5.23T 9.87T 7L 9.99T 67.85T 26.55T 3L 26.28T 25.71T 11.41L 8L 7L 6L 6L 10.81L 7.39Cr 10.94L 74.34L 29.09L 3.62Cr 28.79L 28.17L 12Cr
Net income -24.17L -21.19L -19.63L -18.07L -34.07L -23Cr -34.48L -2.34Cr -91.68L -11Cr -90.73L -88.78L -39Cr -31.96L -28.01L -25.96L -23.89L -45.05L -31Cr -45.59L -3.1Cr -1.21Cr -15Cr -1.2Cr -1.17Cr -52Cr
Net Debt 17.71L 15.52L 14.38L 13.24L 24.96L 17Cr 25.27L 1.72Cr 67.17L 8.36Cr 66.48L 65.05L 29Cr 28.76L 25.21L 23.36L 21.5L 40.54L 28Cr 41.03L 2.79Cr 1.09Cr 14Cr 1.08Cr 1.06Cr 47Cr
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-